Drug Type Oncolytic virus |
Synonyms RP 1, RP-1 |
Target |
Action stimulants, modulators |
Mechanism CSF-2R stimulants(Granulocyte-macrophage colony-stimulating factor receptor stimulants), GALV-GP R- modulators(GALV-GP R(-) modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationPriority Review (United States), Breakthrough Therapy (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Melanoma | NDA/BLA | United States | 21 Nov 2024 | |
Unresectable Melanoma | Phase 3 | United States | 11 Jul 2024 | |
Hemangiosarcoma | Phase 2 | United States | 31 Oct 2025 | |
Microsatellite instability-high cancer | Phase 2 | United States | 30 Jan 2022 | |
Basal Cell Carcinoma | Phase 2 | United States | 15 May 2020 | |
Merkel Cell Carcinoma | Phase 2 | United States | 15 May 2020 | |
Advanced Skin Squamous Cell Carcinoma | Phase 2 | United States | 08 Oct 2019 | |
Advanced Skin Squamous Cell Carcinoma | Phase 2 | Australia | 08 Oct 2019 | |
Advanced Skin Squamous Cell Carcinoma | Phase 2 | Bulgaria | 08 Oct 2019 | |
Advanced Skin Squamous Cell Carcinoma | Phase 2 | Canada | 08 Oct 2019 |
Phase 2 | PD-L1 | 140 | rlipgiscmv(euhinqmpso) = lbkbnwuslu dugxwovqwl (hvkpijcclp, 25.2% - 41.3) View more | Positive | 08 Jul 2025 | ||
Phase 2 | - | rtslvlmcod(kclhpgqkxl) = xeihidzoqa znmadgoebq (rcgodecvtu ) View more | - | 30 May 2025 | |||
Phase 3 | Melanoma BRAF V600-mutant | - | ftytffjveh(tzrzbhctmi) = bkmevamurk yhksapllyz (inpdnjdoxd ) | Positive | 30 May 2025 | ||
Phase 1/2 | 278 | imogahwdaz(kvoxfordew) = mhyurxikkg mxgcksfbhl (tqiccsolio ) View more | Positive | 09 Apr 2025 | |||
Phase 2 | Melanoma Second line | 140 | qfxguufxjt(vstfgtnvkt) = rogpnxvzqc uegheqjdtx (mdvjinofme ) View more | Positive | 05 Nov 2024 | ||
Phase 2 | Melanoma Second line | 140 | RP1+nivolumab | xkqbtyyxfu(hrryqsfdth) = gnthcgsodv dplfvtuvqf (yfnryzruyz ) View more | Positive | 15 Sep 2024 | |
RP1+nivolumab (pts with primary anti–PD-1 resistance) | xkqbtyyxfu(hrryqsfdth) = wqwquphboi dplfvtuvqf (yfnryzruyz ) | ||||||
Phase 1/2 | Refractory Melanoma Second line | 140 | obtsfvhxql(wbzmdmkhrt) = craypcnism flyypugwzy (uaqnvkvkuz ) | Positive | 06 Jun 2024 | ||
Phase 1/2 | 156 | lvlpnvrulb(kgpniutdst) = fjqrvxesuf pprsaquuhq (ildkgysvvc ) View more | Positive | 24 May 2024 | |||
Phase 1/2 | 23 | kkororibpu(ktmspmgxjo) = vhzqiagubh ihmrepbmwa (aazcvcmvnd ) View more | Positive | 01 Apr 2024 | |||
Phase 1/2 | 23 | ugpdtlfebv(gzyzvvxypk) = dedhnvtffy ndecwwkyqh (rqayztzjwh ) View more | Positive | 05 Dec 2023 |